Proteasome Inhibitors: A Novel Class of Potent and Effective Antitumor Agents


ProScript, Inc., Cambridge, Massachusetts 02139; J. A. V. J. P., A. D., D. D. L., C. S. P., P. J. E.; Hoechst Marion Roussel, D-60486, Frankfurt am Main, Germany; [J. M.]; Hoechst Marion Roussel, Bridgewater, New Jersey 08807; S. P.; and Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland 20892 [E. A. S., J. J.]

ABSTRACT

The ubiquitin-proteasome pathway plays a critical role in the regulated degradation of proteins involved in cell cycle control and tumor growth. Dysregulating the degradation of such proteins should have profound effects on tumor growth and cause cells to undergo apoptosis. To test this hypothesis, we developed a novel series of proteasome inhibitors, exemplified by PS-341, which we describe here. As determined by the National Cancer Institute in vitro screen, PS-341 has substantial cytotoxicity against a broad range of human tumor cells, including prostate cancer cell lines. The PC-3 prostate cell line was, therefore, chosen to further examine the antitumor activity of PS-341. In vitro, PS-341 elicits proteasome inhibition, leading to an increase in the intracellular levels of specific proteins, including the cyclin-dependent kinase inhibitor, p21. Moreover, exposure of such cells to PS-341 caused them to accumulate in the G2-M phase of the cell cycle and subsequently undergo apoptosis, as indicated by nuclear condensation and poly(ADP-ribose) polymerase cleavage. Following weekly i.v. treatment of PS-341 to mice bearing the PC-3 tumor, a significant decrease (60%) in tumor burden was observed in vivo. Direct injection of PS-341 into the tumor also caused a substantial (70%) decrease in tumor volume with 40% of the drug-treated mice having no detectable tumors at the end of the study. Studies also revealed that i.v. administration of PS-341 resulted in a rapid and widespread distribution of PS-341, with highest levels identified in the liver and gastrointestinal tract and lowest levels in the skin and muscle. Modest levels were found in the prostate, whereas there was no apparent penetration of the central nervous system. An assay to follow the biological activity of the PS-341 was established and used to determine temporal drug activity as well as its ability to penetrate tissues. As such, PS-341 was shown to penetrate PC-3 tumors and inhibit intracellular proteasome activity 1.0 h after i.v. dosing. These data illustrate that PS-341 not only reaches its biological target but has a direct effect on its biochemical target, the proteasome. Importantly, the data show that inhibition of this target site by PS-341 results in reduced tumor growth in murine tumor models. Together, the results highlight that the proteasome is a novel biochemical target and that inhibitors such as PS-341 represent a unique class of antitumor agents. PS-341 is currently under clinical evaluation for advanced cancers.

INTRODUCTION

The ubiquitin-proteasome pathway is the principle pathway for intracellular protein degradation (1–3). Protein substrates are “marked” with a poly-ubiquitin chain (4) and then degraded to peptides and free ubiquitin by a large multimeric protease, the proteasome, which exists within all eukaryotic cells (1–3). Numerous examples of regulatory proteins have been found to undergo ubiquitin-dependent proteolysis. Many of these proteins function as important regulators of physiological as well as pathophysiological cellular processes. Importantly, the ubiquitin-proteasome pathway plays a significant role in neoplastic growth and metastasis. The ordered and temporal degradation of numerous key proteins (e.g., cyclins, CDK inhibitors, and tumor suppressors) is required for cell cycle progression and mitosis (3).

The proteasome is also required for activation of NF-κB by degradation of its inhibitory protein, IκB (5). NF-κB is required, in part, to maintain cell viability through the transcription of inhibitors of apoptosis, in response to environmental stress or cytotoxic agents (6–9). Stabilization of the IκB protein and blockade of NF-κB activity has been demonstrated to make cells more susceptible to apoptosis (6–8). Furthermore, NF-κB has also been implicated in controlling the cell surface expression of adhesion molecules such as E-selectin, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 (10, 11). These cell adhesion molecules are involved in tumor metastasis and angiogenesis in vivo (12). During metastasis, these molecules direct the adhesion and extravasation of tumor cells to and from the vasculature to distant tissue sites.

Aberrant regulation of cell cycle proteins can result in accelerated and uncontrolled cell division, leading to tumorigenesis, cancer growth, and spread (12). Hence, proteasome inhibitors should arrest or retard cancer progression by interfering with the ordered, temporal degradation of these regulatory molecules. Inhibition of proteasome-mediated IκB degradation may limit metastasis via the attenuation of NF-κB-dependent cell adhesion molecule expression (10, 11) and make dividing cancer cells more sensitive to apoptosis (6–8). Thus, proteasome inhibitors could act through multiple mechanisms to arrest tumor growth, tumor spread, and angiogenesis, offering a novel approach to treating cancer. As such, it is understood that dosing regimens must be optimized to limit the effects of proteasome inhibition in noncancerous cells, thereby establishing a therapeutic index.

Here, we describe the development of a unique series of proteasome inhibitors that are potent, selective, and reversible. These compounds are dipeptide boronic acid analogues that inhibit the chymotryptic activity of the proteasome and, thereby, block activity of the enzyme. By attenuating the degradation of cell cycle regulatory proteins, such agents elicit multiple effects leading to the inhibition of tumor cell growth and to apoptosis. Importantly, the inhibitor potency (Kᵢ) data correlate with the cytotoxicity profile against a panel of 60 human tumor cell lines in vitro as well as with in vivo antitumor activity in human xenograft models, supporting the mechanism of proteasome inhibition. Together, these results suggest that the mechanism of antineoplastic activity of the boronate class of compounds is unique and that proteasome inhibition represents a novel approach to the development of anticancer agents. The activity of PS-341, a representative of such compounds, was chosen to highlight the features of this novel drug class and is currently under Phase I clinical evaluation in advanced cancer patients.

MATERIALS AND METHODS

Chemical Synthesis of Inhibitors and Kᵢ Measurements. Inhibitors were synthesized and purified according to the procedures described in Adams et al.
The inhibition constant ($K_i$) for each inhibitor was measured according to the method of Stein et al. (14) using a fluorometric assay, monitoring peptide substrate cleavage of Z-Leu-Leu-Val-Tyr-amino methyl coumarin ($Z = \text{carboxenolxy}$) by the 20S proteasome.

**Cell Cytotoxicity Assays.** The 60-cell line panel from the NCI has been described previously (15). Each cell line was exposed to the test proteasome inhibitor in five 10-fold dilutions for a period of 48 h. The growth and viability of the treated cells was compared with that of control cells by means of sulforhodamine B anionic dye staining. The results are reported as a series of bar graphs which depict the sensitivities of each cell line to the test agent at various concentrations of the treated cells was compared with that of control cells by means of the method of Stein et al. (13).

**Western Blot Analysis.** PC-3 cells were plated in six-well plates (10^6 cells/well) of 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide assay (17). The final concentration of DMSO was 0.1%. Whole-cell extracts were prepared and analyzed by Western blots for the presence of p21, CDK-4 (Santa Cruz Biotechnology, Santa Cruz, CA), and PARP (Biomol).

**Scintillation Counting.** Radiolabeled [14C]PS-341 (10 μCi/kg) was administered as an i.v. bolus to male rats, which were subsequently sacrificed at 10 min, 1.0 h, 3.6 h, and 24 h. Blood samples were taken at sacrifice, and levels of radioactivity were determined using combustion (Canberra-Packard system). Euthanized animals were then frozen, and sections were taken 96 h later through specific planes to identify organs of interest. Radioactivity levels in tissue were calculated using TINA software (Raytest, Straubenhard, Germany).

**Fluorometric 20S Proteasome Assay.** Cell or tissue sample homogenate (5 μl) was added to 2 ml of substrate buffer (20 mM EDTA, 0.035% SDS, and 60 μM Ys substrate; pH 8.0, 37°C), and the rate of substrate cleavage/20S proteasome activity was determined. Succinyl-Leu-Leu-Val-Tyr-Amido-4-methyl-coumarin (Ys substrate) was obtained from Bachem. Other reagents were obtained from Sigma Chemical Co. (St. Louis, MO). The protein content of the samples was determined using a Coomassie protein assay (Pierce, Rockford, IL).

**Animals.** Male nude mice (18–20 g; n = 51), were obtained from the NCI (Bethesda, MD). Animals were observed for at least 1 week and examined for general health before study initiation. Animals used in these studies were asymptomatic and were housed five per cage in the animal facility at ProScript. Pellets of standard rodent chow (formula 5001; Purina, St. Louis, MO) were available ad libitum throughout the observation and study periods. Cambridge city tap water was provided by water bottles ad libitum. Male Sprague Dawley rats (200–210 g) were purchased from Charles River (Germany) and housed in the animal facility at Hoehst (Frankfurt am Main, Germany). Rats were fed millied diet (Sniff Spezialdiaten GmbH, Soest, Germany) and allowed free access to tap water ad libitum. Fluorescent lighting was controlled automatically in both facilities to provide alternate light and dark cycles of ~12 h each. Temperature and humidity were centrally controlled and recorded daily.

**Xenograft Procedures.** PS-341 drug substance was synthesized at Pro-Script, Inc. (Cambridge, MA). Dose formulations of PS-341 were prepared daily during the course of in vivo studies and were administered in vehicle i.v. using a dose volume of 100 μl per mouse or directly into the tumor in a 10 μl volume. Control groups were administered with the vehicle [98% saline, 0.2% ethanol, and 0.1% ascorbic acid]. Due to the comparatively high levels of PS-341 in the prostate, after i.v. dosing of radiolabeled drug, it was decided to examine the effects of this novel compound in the prostate, PC-3, mouse model.

**Table 1** Structure-activity relationships of 13 boronic acid proteasome inhibitors against purified proteasome activity ($K_i$) and their ability to inhibit cell growth across 60 tumor cell lines (average GI50) from the National Cancer Institute.

<table>
<thead>
<tr>
<th>Compound</th>
<th>Structure</th>
<th>$K_i$ (nm)</th>
<th>Average GI50 (nm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>681226/PS-273</td>
<td>MorphOCONH(CHNaphthyl)CONH(CHisobutyl)OB(OH)2</td>
<td>0.2</td>
<td>6.3</td>
</tr>
<tr>
<td>681227/PS-273</td>
<td>Enantiom-PS-273</td>
<td>2,300</td>
<td>56,000</td>
</tr>
<tr>
<td>681228/PS-296</td>
<td>8-QuinolylsulfonfonylOCONH(CHNaphthyl)CONH(CHisobutyl)OB(OH)2</td>
<td>3.5</td>
<td>17</td>
</tr>
<tr>
<td>681229/PS-303</td>
<td>NH2(CHNaphthyl)CONH(CHisobutyl)OB(OH)2</td>
<td>12</td>
<td>68</td>
</tr>
<tr>
<td>681231/PS-305</td>
<td>MorphOCONH(CHNaphthyl)CONH(CHisobutyl)OB(OH)2</td>
<td>189</td>
<td>4,700</td>
</tr>
<tr>
<td>681234/PS-313</td>
<td>NaphthylCH3(CHNaphthyl)CONH(CHisobutyl)OB(OH)2</td>
<td>58</td>
<td>1,300</td>
</tr>
<tr>
<td>681236/PS-321</td>
<td>MorphOCONH(CHNaphthyl)CONH(CHisobutyl)OB(OH)2</td>
<td>0.5</td>
<td>6.6</td>
</tr>
<tr>
<td>681237/PS-333</td>
<td>CH3NH(CHNaphthyl)CONH(CHisobutyl)OB(OH)2</td>
<td>3.5</td>
<td>13</td>
</tr>
<tr>
<td>681239/PS-341</td>
<td>PyrazolOCONH(CHPheCONH(CHisobutyl)OB(OH)2</td>
<td>0.6</td>
<td>3.9</td>
</tr>
<tr>
<td>681242/PS-364</td>
<td>PhCH3CH2(Naphthyl)CONH(CHisobutyl)OB(OH)2</td>
<td>1,500</td>
<td>10,000</td>
</tr>
<tr>
<td>683060/PS-325</td>
<td>2-QuinolylCONH(CHisobutyl)OB(OH)2</td>
<td>2</td>
<td>34</td>
</tr>
<tr>
<td>683094/PS-352</td>
<td>PhCH3CH2(Naphthyl)CONH(CHisobutyl)OB(OH)2</td>
<td>0.1</td>
<td>10</td>
</tr>
<tr>
<td>683098/PS-383</td>
<td>PyridylOCONH(CHPheCONH(CHisobutyl)OB(OH)2</td>
<td>0.6</td>
<td>10</td>
</tr>
</tbody>
</table>

Downloaded from cancerrates.aacrjournals.org on October 22, 2017. © 1999 American Association for Cancer Research.
xenograft tumor model. Animals were treated when the tumors became palpable (>300 mm³). Studies were performed according to Institutional Animal Care and Use Committee-approved procedures. Tumor volumes were calculated from the equation below using caliper measurements taken twice a week:

\[ \text{Tumor volume (mm}^3) = \text{Length (mm)} \times \text{width (mm)} \times \text{shortest measurement (mm)} \]

**Statistical Analysis.** Tumor volume data were analyzed using ANOVA and a post hoc Dunnett’s t test, for which \( P < 0.05 \) was deemed significant using a two-tailed test.

**RESULTS**

**Synthesis of Proteasome Inhibitors.** One of the first proteasome inhibitors synthesized was MG-132, a peptide aldehyde based on calpain inhibitor I (19). However, MG-132 was found to be nonselective because it inhibits other enzymes (20). The realization that the proteasome was a threonine protease (21) supported the concept that boronic acids would be potent and selective inhibitors of the proteasome (14). Such compounds form covalent and reversible complexes with the proteasome and are much more potent than their corresponding aldehydes (13). A series of selective inhibitors were prepared with \( K_i \)'s spanning 5 logs of potency (Table 1). The stereospecificity for drug binding is clearly demonstrated by the activity of PS-273 and the lack of potency by its inactive enantiomer PS-293 (Fig. 1). One low molecular weight, water-soluble dipeptide boronic acid, PS-341, with a \( K_i \) of 0.6 nM, was selected for intensive study (Fig. 1, inset).

**PS-341 Is Cytotoxic for PC-3 Cells in Vitro.** The NCI uses, as its primary preclinical assay, an in vitro cytotoxicity screen comprised of 60 cell lines derived from multiple human tumors (15). The average growth inhibition of 50% (GI50) value for PS-341 across the entire NCI cell panel was 7 nM. Moreover, when 13 dipeptide proteasome inhibitors from the boronate series were examined, a strong correlation (Pearson coefficient, \( r^2 = 0.92 \)) was noted after plotting \( K_i \) versus GI50 values (Fig. 1). This finding associates the intrinsic potency of this class of compounds with their antiproliferative activity in cell culture assays, confirming their activity through a biological target, the proteasome. Using the NCI’s algorithm COMPARE (16), we compared the “fingerprint” for PS-341-induced cytotoxicity to the historical file of 60,000 compounds and found it to be unique, with little correlation to other “standard” or investigational agents. In addition, PS-341 was shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with...
a concentration that inhibited 50% of the proteolysis (IC_{50}) of ~0.1 μM (data not shown).

In the NCI in vitro screen the prostate tumor PC-3 cell line (22) was shown to be sensitive to the antiproliferative effects of PS-341. To examine the potential mechanism(s) of proteasome inhibitor-induced cytotoxicity, PS-341 was studied in detail in this prostate cell line. Numerous proteins control cell cycle progression, including the tumor suppressor p53 and the CDK inhibitors p21 and p27 (12). PC-3 cells are p53 null (23), and hence, this protein is not required for PS-341-induced cytotoxicity in this cell line. In fact, PS-341 was demonstrated to be cytotoxic in multiple cell lines in the NCI screen, independent of p53 status (data not shown). Protein levels of p21 were measured to exemplify the activity of PS-341 in cells. Although very little p21 protein was detected in untreated cells, levels were significantly increased with 10 nM PS-341 (Fig. 2A) occurring 24 h after drug addition. The increase in p21 protein levels could be detected 4 h after PS-341 treatment (data not shown). The increase in p21 led to an inhibition in the activity but not the levels of CDK-4 after 8 h (data not shown).

The ability of PS-341 to inhibit cell cycle progression was determined by propidium iodide staining and FACS analysis. Treatment of PC-3 cells with PS-341 (100 nM) for 8 h resulted in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1 (Fig. 2B). A slight increase in the number of cells in S phase was also noted. These effects preceded cytotoxicity and support other data showing that increased p21 levels, in addition to blocking the G1-S transition, also block the G2-M transition leading to an accumulation of cells in G2-M (24, 25). These results clearly demonstrate that PS-341 effects proteins that control cell cycle progression.

Inhibiting the degradation of key cell cycle regulatory proteins causes a disparity in the proliferative signals and can eventually lead to apoptosis. Indeed, nonselective proteasome inhibitors can arrest cell growth and activate apoptosis (26, 27). Thus, the effect of PS-341 on cell viability was evaluated. The PS-341 doses at which 50% of PC-3 cells were killed at 24 and 48 h were determined to be 100 and 20 nM, respectively (Fig. 2C). Moreover, nuclear condensation was noted 16–24 h after the addition of PS-341 (~100–500 nM; data not shown). Activation of caspases occurs in cells undergoing apoptosis, and cleavage of PARP is used as an indicator of apoptosis (28). Additional studies showed that PS-341 treatment leads to PARP cleavage in a time-dependent manner (Fig. 3A), with concentrations as low as 100 nM being effective at 24 h (Fig. 3B), demonstrating that PS-341 initiates apoptosis in PC-3 cells. However, because PARP cleavage and nuclear DNA condensation were not apparent until 16 h, a time after which growth arrest was apparent, the data indicate that growth arrest precedes apoptosis and cytotoxicity.

**PS-341 Inhibits PC-3 Tumor Growth in Nude Mice.** The NCI examined initial activity in vivo with a hollow fiber assay (29), which recorded very good activity for PS-341 and a series of analogues (data not shown). This gave impetus to examine antitumor activity for PS-341 in human xenografts. For example, s.c. implantation of human PC-3 tumor cells into nude mice elicits a large tumor that is eventually

---

**Fig. 4.** Effect on PC-3 tumor growth in mice after four weekly i.v. injections of vehicle or PS-341 (a) or after direct injection of PS-341 or vehicle (b) into the PC-3 tumor on 4 consecutive days. Data points, tumor volumes provided as mean volumes (mm$^3$); bars, SE. Arrows, treatment times.
lethal. PS-341 was administered to mice injected with PC-3 cells when the tumors became palpable (>300 mm³). Two studies were undertaken. First, mice bearing PC-3 tumors were injected with PS-341 (0.3 or 1.0 mg/kg) i.v. once weekly for 4 weeks, and tumor volumes were recorded. Weekly i.v. treatment with PS-341 (1.0 mg/kg) resulted in a significant decrease in tumor growth (~60%; P < 0.05), as determined by measurement of tumor volume. The lower dose of PS-341 (0.3 mg/kg) produced a 16% decrease in tumor volume but did not reach significance (Fig. 4A). PS-341 significantly decreased the tumor volume although distribution of the compound to the skin is limited (see below). To further explore the antitumor utility of PS-341, the drug was administered directly into PC-3 tumors in a second study. On 4 consecutive days, PS-341 (1.0 mg/kg) was administered (10 μl) into established PC-3 tumors, and results clearly showed a dramatic decrease in tumor burden (Fig. 4B). In addition to the large decrease in tumor volume (70%), two of five mice (40%) had no detectable tumors at the end of the study. At well-tolerated doses, treatment with PS-341 clearly suppressed tumor growth. These data highlight the full antitumor potential of PS-341. Similar effects have been observed in other murine tumors and human xenograft tumors (data not shown). No adverse effects of drug treatment were noted during any of these studies.

To determine the pharmacodynamics of i.v. administered PS-341, WBCs, brain, colon, liver, muscle, prostate, testes, and PC-3 tumor tissue were collected following PS-341 treatment. Subsequently, residual 20S proteasome activity was determined in these samples, and results showed that PS-341 elicited a dose-dependent decrease in 20S proteasome activity. As an example, in WBCs 1.0 h after treatment, 20S proteasome activity was significantly decreased (Fig. 5A) and returned to baseline after 24 h. Similar effects were noted in other tissues, except the brain and testes, where no proteasome inhibition was observed, indicating that the drug did not penetrate these tissues (data not shown). Of great interest, 1.0 h after i.v. administration of PS-341, a significant decrease in 20S proteasome activity was noted in s.c. implanted PC-3 tumors, up to 40% (Fig. 5B). Considering that the tumor was exposed to only a fraction of the administered PS-341, the decrease in 20S proteasome activity in these tumor samples illustrates that the drug clearly has a significant effect at its target site and that such proteasome inhibition ultimately leads to decreased tumor burden, as demonstrated above.

i.v. dosing with radiolabeled [14C]PS-341 to rats allowed analysis of the drug’s distribution as determined by quantitative whole-body autoradiography. The highest radioactivity levels 10 min after drug administration were in the adrenals, kidney cortex, liver, prostate, and spleen. Lower levels were found throughout other organs, including the skeletal muscle, skin, and blood. The brain, spinal cord, eye, and testes had levels below the limits of quantitation. In the gastrointestinal tract, the highest radioactivity levels were found in the small intestine (Fig. 6A). At later time points (3 and 6 h) the same general profile was observed, although radioactivity levels in the gastrointestinal tract were the highest in the large intestine. At 24 h, the highest radioactivity levels were observed in the same organs as those seen initially but were reduced from 6 h (Fig. 6B). Furthermore, that no detectable levels were observed in the brain, spinal cord, eye, or testes suggest that PS-341 does not readily cross tight endothelial cell junctions. These data support the lack of 20S proteasome inhibition reported above in these organs. Because the gastrointestinal tract contained high levels of radioactivity, this distribution profile is indicative of a compound excreted via the bile. This was confirmed in rats with bile duct cannuiae, where the majority (66%) of the radiolabeled drug was, indeed, excreted into the bile; the remainder was in the urine. Data from the 20S proteasome assay showed that neither fluid contained inhibitory activity, suggesting that only metabolized PS-341 was excreted (data not shown).

The low levels detected in skin suggest that s.c. implanted tumor cells would have limited exposure to i.v. administered PS-341. Additional radiolabeled drug experiments in mice, bearing PC-3 tumors, also showed that i.v. PS-341 had a similar distribution to that observed in rats and that access of the drug to the skin and the tumor was limited (Fig. 7). However, only <1.0% of the injected PS-341 was detected in the tumor, but this was sufficient to significantly inhibit 20S proteasome activity in this tissue (Fig. 5B). Together, these studies imply that the potency of PS-341 in murine s.c. xenograft models may be underestimated. This concept appears to be confirmed because direct administration of PS-341 into the PC-3 tumor evoked complete tumor regression in 40% of the animals (Fig. 4B).

**DISCUSSION**

The fundamental goal of many chemotherapeutic agents currently used to treat neoplastic disease is to interfere with tumor cell metabolism and the mitotic process by blocking protein and DNA synthesis. This report describes a novel series of very selective inhibitors of the
proteasome that serve to block cellular protein degradation. Although protein turnover is required for normal cell function, there is much data linking protein turnover to cell cycle regulation (3). As such, these data support a causal relationship between inhibition of the proteasome and inhibition of cell growth in human tumor cell lines \textit{in vitro}. The structure-activity relationship determined here correlates very well to tumor cell growth inhibition and provided strong support that the inhibition of the biochemical target, the proteasome, was directly related to the biological effect of the compounds. Moreover, the \textit{in vitro} data suggest that the proteasome has a significant role in maintaining cell viability and controlling cell proliferation, confirming earlier reports (30, 31).

The development of selective and potent proteasome inhibitors was based upon the above concept, with the aim of arresting uncontrolled proliferation of tumors through a multitude of mechanisms. Proteasome-induced cytotoxicity could potentially result from multiple events, including the stabilization and deregulated function of cyclins, CDK inhibitors, tumor suppressor proteins, IkB, and a large number of other proteins associated with cell cycle progression. Our report highlights the capacity of proteasome inhibitors to induce cell cycle arrest and apoptosis through inhibition of the proteasome and illustrates that these effects occur in a broad range of tumor cells.

Analysis of the inhibition data in the NCI cell line panel indicates that the proteasome inhibitors have potent and wide-ranging antitumor activity with a unique pattern of tumor inhibition, as judged by the COMPARE program (16). Further demonstration of the utility of such
PS-341 significantly inhibited cell cycle progression and cause apoptosis. This new class of agents, exemplifies their activity in the NCI hollow fiber assay, determining using scintillation counting in homogenized samples; bars: SE.

At doses that are permissive to animals, i.v. treatment of PS-341 can suppress tumor growth in many murine and human xenograft tumors. Here, we focused on the PC-3 xenograft and showed the potent antitumor effects of PS-341 when it is given as a weekly i.v. treatment. PS-341 significantly (*P < 0.05) decreased the tumor volume in these studies, although distribution of the compound to the skin is limited. The activity of PS-341 in orthotopic tumor models is currently being evaluated. However, as a proof-of-concept study, direct administration of PS-341 into the PC-3 tumor induced a dramatic decrease in tumor burden and actually produced a 40% cure rate, clearly highlighting the potential for such compounds in cancer therapy.

Due to the novel nature of proteasome inhibitors as therapeutics, it was decided to undertake a full toxicological evaluation of PS-341, not only in rodents but in the highest species possible, primates. On the basis of these studies, maximum tolerated doses and side effect profiles of PS-341 were established. The main adverse effect noted in both species was gastrointestinal toxicity as anticipated from the distribution studies. In primates, this was seen as a decrease in food intake (anorexia), emesis, and diarrhea, which all occurred in a dose-related manner. No other signs of toxicity were noted in these studies, although full clinical chemistry, hematology, and microscopic analysis of over 40 tissues were examined. Modest effects of PS-341 were seen in the spleen and the thymus, where lymphocytic depletion was reported. These findings are not unexpected because there are reports in the literature with other proteasome inhibitors showing that they regulate T-cell proliferation (32). Of interest, PS-341 did not induce bone marrow toxicity, suggesting that it either does not affect hematopoietic cells here or that it has limited access to such cells.

The *ex vivo* 20S proteasome assay will be invaluable not only to follow the pharmacodynamics of PS-341 but also to help in early clinical trials to evaluate its effectiveness at its biochemical target, the proteasome, and its intended site, the tumor. The assay may also be used to correlate proteasome activity with toxicity to help determine dose escalation in clinical trials.

Although several reports document the cytotoxic effects of other less potent and nonselective proteasome inhibitors (26, 27, 30, 31), our findings represent the first attempt to systematically correlate proteasome inhibition potency with tumor cell killing using a novel, selective family of inhibitors. Furthermore, we demonstrate that such agents are broadly active against multiple tumor cell types *in vitro* and *in vivo*. The full impact of the antitumor activity of PS-341 will be determined upon completion of the clinical trials.

ACKNOWLEDGMENTS

We thank Dr. Craig Hilton for his help with the FACS analysis and Dr. Al Baldwin for his constructive comments on the manuscript.

REFERENCES


10. Zitron, L., Melandri, F., and Dick, L. Inhibition of the chymotryptic-like proteolytic activity of rabbit muscle 20S proteasome. Proteasome isolation, purification, and assays were performed as previously described. Biochemistry, 55: 3899–3908, 1996.


14. Stein, R. L., Melandri, F., and Dick, L. Inhibition of the chymotryptic-like proteolytic activity of rabbit muscle 20S proteasome. Proteasome isolation, purification, and assays were performed as previously described. Biochemistry, 55: 3899–3908, 1996.


Proteasome Inhibitors: A Novel Class of Potent and Effective Antitumor Agents


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/59/11/2615

Cited articles
This article cites 31 articles, 14 of which you can access for free at:
http://cancerres.aacrjournals.org/content/59/11/2615.full#ref-list-1

Citing articles
This article has been cited by 100 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/59/11/2615.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.